ACCELERATOR PRODUCTION OF CU-64 FOR PET AND RADIOTHERAPY

该项目的目标是开发一种高效的技术，用于 利用小型生物医用材料生产高比活度铜 加速器。铜-(t1/2=12.7hr)是一个中间的半衰期 发射正电子的放射性核素已被证明是一种有用的 正电子发射断层扫描(PET)用放射性示踪剂及前景看好的 治疗结直肠癌的放疗剂。铜-是 目前是反应堆生产的，因为这种放射性核素只能 在少数反应堆设施中生产，它的可用性是 非常有限。 我们建议开发一种创新的放射性同位素靶标和分离 将允许生产临床上有用的数量的系统 的铜-用常规的聚酯回旋加速器以及与低 最近可用于PET的能量直线加速器。 铜-将由64Ni(p，n)反应生成。在第一阶段， 将确定最佳的靶照射条件，并采用技术 将开发用于分离和提纯高纯度的 活性铜-和用于回收镍-靶材。 这些研究将导致设计一种自给自足、自动化的 铜加速剂生产及提纯系统-- 成像和放射治疗所需的数量。 拟议的商业应用：铜-生产系统 在这个程序中开发的将立即用于研究人员 使用医院的回旋加速器和现有的基于放射性药物的 加速器设施。是否有一个方便的系统可供 现场、按需生产铜-将为进一步 铜标记成像和放射治疗方案的研究进展 化合物。

The goal of this project is to develop an efficient technique for the production of high specific activity copper-64 with small biomedical accelerators. Copper-64 (t 1/2 = 12.7 hr.) is an intermediate half-life positron emitting radionuclide which has been shown to be a useful radiotracer for positron emission tomography (PET) as well as a promising radiotherapy agent for the treatment of colorectal cancer. Copper-64 is currently reactor-produced and, because this radionuclide can only be produced at a small number of reactor facilities, its availability is extremely limited. We propose to develop an innovative radioisotope target and separation system which will allow the production of clinically useful quantities of copper-64 with conventional PET cyclotrons as well as with the low energy linear accelerators which have recently become available for PET. Copper-64 will be produced by the 64Ni(p,n) reaction. In Phase I, the optimum target irradiation conditions will be determined, and techniques will be developed for the separation and purification of high specific activity copper-64 and for recovery of the nickel-64 target material. These studies will lead to the design of a self-contained, automated system for the accelerator production and purification of copper-64 in the quantities required for imaging and radiotherapy. PROPOSED COMMERCIAL APPLICATION: The copper-64 production system developed in this program would be of immediate use to researchers having access to hospital-based cyclotrons and to existing radiopharmacy-based accelerator facilities. The availability of a convenient system for the on-site, on-demand production of copper-64 will facilitate the further development of imaging and radiotherapy protocols using copper-labeled compounds.